| Literature DB >> 24896210 |
Morgana Moretti1, Filipe C Matheus1, Paulo A de Oliveira1, Vivian B Neis1, Juliana Ben1, Roger Walz1, Ana Lucia S Rodrigues1, Rui Daniel Prediger1.
Abstract
Agmatine, a cationic polyamine synthesized after decarboxylation of L-arginine by the enzyme arginine decarboxylase, is an endogenous neuromodulator that emerges as a potential agent to manage diverse central nervous system (CNS) disorders. Consistent with its neuromodulatory and neuroprotective properties, there is increasing number of preclinical studies demonstrating the beneficial effects of exogenous agmatine administration on depression, anxiety, hypoxic ischemia, nociception, morphine tolerance, memory, Parkinson`s disease, Alzheimer`s disease, traumatic brain injury related alterations/disorders and epilepsy. The aim of this review is to summarize the knowledge about the effects of agmatine in CNS and point out its potential as new pharmacological treatment for diverse neurological and neurodegenerative diseases. Moreover, some molecular mechanisms underlying the neuroprotective effects of agmatine will be discussed.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24896210 DOI: 10.2741/E710
Source DB: PubMed Journal: Front Biosci (Elite Ed) ISSN: 1945-0494